VLBW

Pediatric Academic Societies Meeting Includes Symposium on Cost-Effectiveness of Implementing Exclusive Human Milk-Based Nutrition for Premature Infants

Retrieved on: 
Friday, May 3, 2024
NICU, Hospital, Health, Adolescence, Infant, Length of stay, BMBF, Parenteral nutrition, Patient, VLBW, Hospice and palliative medicine, Child, FAAP, PAS

DUARTE, Calif., May 3, 2024 /PRNewswire/ -- Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, announced today that Dr. Rangasamy Ramanathan, professor of pediatrics division chief, division of neonatal medicine, Los Angeles General Medical Center and PIH Good Samaritan Hospital, will present published data on the financial and clinical benefits of implementing an Exclusive Human Milk Diet (EHMD) for very low birth weight (VLBW) infants during the 2024 Pediatric Academic Societies (PAS) Meeting on Saturday, May 4, 6:30-8 p.m. ET, in Toronto.

Key Points: 
  • PAS connects thousands of leading pediatric researchers, clinicians, and medical educators worldwide to advance scientific discovery and promote innovation in child and adolescent health.
  • "We saw significant reductions in length of stay and days on parenteral nutrition, which directly translated to substantial cost savings for our NICU."
  • "We encourage PAS attendees to attend the symposium to learn more about the clinical and financial benefits of EHMD implementation."
  • Extensive real-world data affirm EHMD adoption enables critical health improvements for premature infants and major cost reductions for hospitals.

Prolacta Bioscience Recognizes Advances in Preterm Care During NICU Awareness Month

Retrieved on: 
Tuesday, September 19, 2023
Breast Cancer Awareness Month, University, Pediatrics, BPD, NICU, Hospital, Late preterm infant, VLBW, Nicu Ceaușescu, Infant, Retinopathy, Premature, Risk, Master of Science, BioMed Central, ROP, Intensive care unit, Heart rate, Health, Bronchopulmonary dysplasia, NEC, Dairy, Birth control, Health insurance, MD

DUARTE, Calif., Sept. 19, 2023 /PRNewswire/ -- There have been incredible breakthroughs in neonatal care over the last decade, with premature infants born as early as 22 weeks now surviving and thriving. From heart rate monitoring to lung therapies, one of the biggest changes in the NICU has been how these fragile, premature infants are fed. This Neonatal Intensive Care Unit (NICU) Awareness Month, Prolacta Bioscience® recognizes how proper care, including critical nutrition in the NICU — with 100% human milk-based nutrition — has improved the health and well-being of preterm infants.

Key Points: 
  • From heart rate monitoring to lung therapies, one of the biggest changes in the NICU has been how these fragile, premature infants are fed.
  • This Neonatal Intensive Care Unit (NICU) Awareness Month, Prolacta Bioscience ® recognizes how proper care, including critical nutrition in the NICU — with 100% human milk-based nutrition — has improved the health and well-being of preterm infants.
  • Today, the world's leading clinicians and NICUs offer Prolacta's human milk-based nutritional products as the standard of care because they have been shown to reduce some of the most serious complications of prematurity.
  • "NICU Awareness Month reminds us to take a step back and reflect upon how far we've come in neonatal care over the last decade.

New Study Shows Prolacta's Human Milk-Based Nutritional Fortifiers Save Hospital NICUs Up to $3.4M Annually

Retrieved on: 
Tuesday, June 27, 2023
Hospice and palliative medicine, Exclusive, University, Pediatrics, BPD, NICU, Late preterm infant, VLBW, Retinopathy, Hospital, Premature, Master of Science, BioMed Central, ROP, Infant, Bronchopulmonary dysplasia, NEC, Nursing, Birth control, Health insurance, MD

DUARTE, Calif., June 27, 2023 /PRNewswire/ -- Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, today announced a peer-reviewed report demonstrating significant annual cost savings that ranged from $500,000 to $3.4 million per hospital after the implementation of Prolacta's Exclusive Human Milk Diet (Prolacta's EHMD) for preterm infants in the neonatal intensive care unit (NICU).

Key Points: 
  • DUARTE, Calif., June 27, 2023 /PRNewswire/ -- Prolacta Bioscience , the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, today announced a peer-reviewed report demonstrating significant annual cost savings that ranged from $500,000 to $3.4 million per hospital after the implementation of Prolacta's Exclusive Human Milk Diet (Prolacta's EHMD) for preterm infants in the neonatal intensive care unit (NICU).
  • NICU leaders from seven U.S. hospitals varying in size, geographic setting, patient population, and funding levels contributed to the publication in BMC Pediatrics titled "Implementing an Exclusive Human Milk Diet for Preterm Infants: Real-World Experience in Diverse NICUs."
  • The study found:
    Of the five hospitals reporting financial data, all realized significant cost avoidance after implementing Prolacta's EHMD, with savings ranging from $515,113 to $3,369,515 per institution annually from a reduction in comorbidities and shorter lengths of stay among very low birth weight (VLBW) infants.1
    Implementation of Prolacta's EHMD resulted in a reduction in the total (medical and surgical) necrotizing enterocolitis (NEC) rate, regardless of the size or level of care of the NICU, as well as reductions in bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), and late-onset sepsis — all common complications of prematurity.1
    VLBW infants fed Prolacta's EHMD also experienced shorter NICU stays at five of the seven hospitals, savings ranging from $307,916 to $2,520,000 per institution annually.1
    The study emphasizes that the cost of Prolacta's EHMD represents a fraction of the usual cost of care for a VLBW infant — approximately $12,500 per infant for an EHMD over a 90-day NICU stay, compared to a total NICU cost of $693,000 to $774,000 for 90 days, depending on level of care.2,3
    "This study provides real-world evidence that an EHMD is not only effective in reducing comorbidities in very preterm infants but also saves money regardless of the institution's size or level of care," said lead author Jonathan R. Swanson, MD, MSc, of the University of Virginia Children's Hospital in Charlottesville.

Breaking Data on the Efficacy and Cost-Effectiveness of an Exclusive Human Milk Diet for Premature Infants To Be Presented at the American Academy of Pediatrics 2022 National Conference

Retrieved on: 
Friday, October 7, 2022
AAP, Method, LinkedIn, Late preterm infant, Jean-Louis Vincent, Lactoferrin, Growth, Hospital, Conference, Infant, Premature, Immunity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Evidence-based medicine, Patient, Research, Twitter, Pacific Time Zone, Instagram, Virginia Commonwealth University, MPH, Science, Milk, Food, Health maintenance organization, FDA Adverse Event Reporting System, American Academy of Pediatrics, Mortality, Doctor of Philosophy, Antibody, Health, Pasteurization, ELBW, Disease, National Conference, Nutritional science, Children's Hospital, Safety, NICU, American Academy, Anaheim Convention Center, UHT, Meta-analysis, VLBW, FDA, Pharmaceutical industry, Facebook, MD

One study based on real-world data from seven U.S. hospitalsdemonstrates the efficacy and cost-effectiveness of an EHMD for premature infants.

Key Points: 
  • One study based on real-world data from seven U.S. hospitalsdemonstrates the efficacy and cost-effectiveness of an EHMD for premature infants.
  • "These collaborative data fill gaps in evidence-based medicine for NICU leaders and provide support for implementing an EHMD for very preterm infants," Dr. Fox said.
  • The major difference between cow milk-based and human milk-based products is the composition notably, the bioactive components that are unique to human milk.
  • Prolacta maintains the industry's strictest quality and safety standards for screening, testing, and processing donor human milk.

Adding a Single Key Gut Bacterium, B. infantis EVC001 to Human Milk Feeding Protocols May Help in the Managed Care of Very Low Birth Weight Infants

Retrieved on: 
Wednesday, January 26, 2022
Research, Baby, Maternity, Clinical Trials, Biotechnology, Managed Care, Health, Consumer, General Health, Science, Medicine, NEC, Inflammation, Research, Oregon Health & Science University, The Journal of Pediatrics, Mortality, Indiana University, Late preterm infant, Infant, Necrotizing enterocolitis, Incidence, VLBW, OHSU, No, Medical record, Pharmaceutical industry

Sub-group analysis of extremely low birth weight (ELBW) infants also demonstrated a statistically significant reduction in NEC rates in infants fed EVC001 (n=75) compared to the No EVC001 cohort (n=125).

Key Points: 
  • Sub-group analysis of extremely low birth weight (ELBW) infants also demonstrated a statistically significant reduction in NEC rates in infants fed EVC001 (n=75) compared to the No EVC001 cohort (n=125).
  • There were no cases of NEC-associated mortality in the EVC001 cohort, which was significant for both the overall EVC001 cohort and the ELBW subgroup.
  • Prematurity and very low birth weight is associated with serious gastrointestinal challenges, such as NEC, that adversely affect morbidity and mortality.
  • NICU-based human milk programs are a major step forward in the care of preterm infants, and probiotics are being considered as the next frontier.

Global Parenteral Nutrition Market (2021 to 2027) - Featuring Baxter International, Grifols and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 23, 2021
Health, Other Health, Laryngeal cancer, Medicine, Adoption, Vitamin, Route of administration, Crohn's disease, Patient, Short bowel syndrome, Nutrient, Parenteral nutrition, Maximal and minimal elements, Electrolyte, Administration, World Health Organization, Action, Mineral, Vitamins & Minerals, Infection, Lipid, Growth, Fats, Protein, Survival, COVID-19, Stomach, Feeding tube, Esophageal cancer, Ulcerative colitis, Cancer, VLBW, World, Malnutrition, CAGR, Heifer International, Dietary supplement, Carbohydrate, Hunger

The global parenteral nutrition market size is expected to reach $10.9 billion by 2027, rising at a market growth of 8.1% CAGR during the forecast period.

Key Points: 
  • The global parenteral nutrition market size is expected to reach $10.9 billion by 2027, rising at a market growth of 8.1% CAGR during the forecast period.
  • Parenteral nutrition (parenteral nutrition), or intravenous feeding, provides liquid nutrients such as proteins, vitamins, fats, electrolytes, minerals, and carbohydrates.
  • Additionally, the requirement for parenteral nutrition (parenteral nutrition) to appropriately balance amino acids, lipids, vitamins, minerals, and other nutrients is expected to create bright growth prospects for the growth of the parenteral nutrition market.
  • Due to their increasing occurrence, the global parenteral nutrition market is expected to be propelled in the upcoming years.